Q1 2026 · 13F-HR
Novo Holdings A/Sholdings as filed
Filed 2026-05-15 · accession 0001388325-26-000026
$1.23B
Reported value
22
Positions
2026-03-31
Period end
The Brief · Novo Holdings A/S · Q1 2026
AI · grounded in 13F
Novo Holdings A/S exited its position in ZBIO, reducing its exposure by $52.6M. The fund also closed its position in INSM for $34.8M and established a new position in XENE worth $28.2M. Additionally, the fund trimmed its holdings in VALN by 54.1% and ASML by 16.7%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $168.5M | 13.7% | 5,350,000 | Common | SOLE |
| 11271J107 | BN | BROOKFIELD CORP | $141.5M | 11.5% | 3,496,245 | Common | SOLE |
| N07059210 | ASML | ASML HOLDING N V | $125.4M | 10.2% | 94,946 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $122.4M | 9.92% | 1,325,000 | Common | SOLE |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $74.9M | 6.07% | 3,686,622 | Common | SOLE |
| 79466L302 | CRM | SALESFORCE INC | $73.4M | 5.95% | 393,187 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $56.3M | 4.56% | 1,550,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $50.2M | 4.07% | 1,280,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $50.0M | 4.05% | 860,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $49.4M | 4.01% | 1,750,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $44.8M | 3.63% | 1,942,142 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $39.1M | 3.17% | 2,000,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $38.1M | 3.08% | 1,200,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $37.9M | 3.07% | 450,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $37.3M | 3.02% | 660,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $34.0M | 2.75% | 3,650,737 | Common | SOLE |
| 01609W102 | BABA | ALIBABA GROUP HLDG LTD | $32.3M | 2.62% | 257,327 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $28.2M | 2.29% | 485,438 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $19.6M | 1.59% | 2,185,923 | Common | SOLE |
| 92025Y103 | VALN | VALNEVA SE | $6.6M | 0.54% | 1,057,421 | Common | SOLE |
| 51655R200 | LNZA | LANZATECH GLOBAL INC | $2.5M | 0.21% | 158,148 | Common | SOLE |
| 57142B104 | MQ | MARQETA INC | $1.8M | 0.15% | 441,558 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.